AstraZeneca's COVID-19 Prevention Therapy Cuts Risk Of Infection In Patients With Weaker Immunity, Data Shows
AstraZeneca's COVID-19 Prevention Therapy Cuts Risk Of Infection In Patients With Weaker Immunity, Data Shows
Thursday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the SUPERNOVA Phase 3 COVID-19 pre-exposure prophylaxis (prevention) trial.
週四，阿斯利康公司（納斯達克股票代碼：AZN）公佈了SUPERNOVA 3期 COVID-19 暴露前預防（預防）試驗的高水平結果。
The study showed AstraZeneca's sipavibart (formerly AZD3152), an investigational long-acting antibody (LAAB), demonstrated a statistically significant reduction in the incidence of symptomatic COVID‐19 compared to control (tixagevimab/cilgavimab or placebo) in immunocompromised patients.
該研究表明，與對照組（tixagevimab/cilgavimab或安慰劑）相比，阿斯利康的sipavibart（前身爲 AZD3152）是一種正在研究的長效抗體（LAAB），在免疫功能低下患者中，症狀COVID‐19的發病率在統計學上顯著降低。
The trial met both dual primary endpoints: Relative risk reduction of symptomatic COVID-19 caused by any SARS-CoV-2 variant and the relative risk reduction of infections caused by SARS-CoV-2 variants not containing the F456L mutation.
該試驗滿足了兩個主要終點：由任何 SARS-CoV-2 變體引起的有症狀的 COVID-19 的相對風險降低，以及由不含有 F456L 突變的 SARS-CoV-2 變體引起的感染的相對風險降低。
SUPERNOVA demonstrated the potential benefit of sipavibart in an evolving variant landscape.
SUPERNOVA展示了sipavibart在不斷變化的變體格局中的潛在好處。
Immunocompromised people include those with blood cancer, organ transplant recipients, patients with end-stage renal disease requiring dialysis, patients receiving B-cell depleting therapy within the past year, and those taking immunosuppressive medications, AstraZeneca said.
阿斯利康說，免疫功能低下的人群包括血癌患者、器官移植接受者、需要透析的終末期腎臟疾病患者、在過去一年內接受B細胞消耗治療的患者以及服用免疫抑制藥物的患者。
Despite accounting for approximately 4% of the population, immunocompromised patients make up about 25% of COVID-19 hospitalizations, ICU admissions, and deaths, even after multiple doses of COVID-19 vaccines.
儘管約佔人口的4％，但免疫功能低下的患者約佔COVID-19 住院、重症監護病房住院和死亡人數的25％，即使在接種了多劑量的 COVID-19 疫苗後也是如此。
Sipavibart was well tolerated in the trial and preliminary analyses show adverse events were balanced between the control and sipavibart arms.
西帕維巴特在試驗中的耐受性良好，初步分析表明，對照組和西帕維巴特組之間的不良事件保持了平衡。
The data will be presented at a forthcoming medical meeting. AstraZeneca is in dialogue with regulatory authorities on potential authorization or approval pathways.
這些數據將在即將舉行的醫學會議上公佈。阿斯利康正在與監管機構就潛在的授權或批准途徑進行對話。
AstraZeneca licensed Sipavibart in May 2022 from RQ Biotechnology.
阿斯利康於 2022 年 5 月向 RQ Biotechnology 授予了 Sipavibart 的許可。
Recently, AstraZeneca declared a worldwide cessation of its COVID-19 vaccine, Vaxzevria, due to an "excess of updated vaccines."
最近，阿斯利康宣佈全球停止使用其 COVID-19 疫苗Vaxzevria，原因是 “更新後的疫苗過多”。
Last month, AstraZeneca, while contesting the claims alleging its vaccine caused death and serious injury, has acknowledged in court documents that its vaccine can, in rare instances, cause thrombosis with Thrombocytopenia Syndrome (TTS), a condition characterized by blood clots and low blood platelet counts.
上個月，阿斯利康在對指控其疫苗造成死亡和重傷的指控提出異議時，在法庭文件中承認，其疫苗在極少數情況下會導致血小板減少綜合症（TTS）的血栓形成，血小板減少綜合徵是一種以血栓和低血小板計數爲特徵的疾病。
Price Action: AZN shares are down 0.04% at $76.94 at the last check on Thursday.
價格走勢：在週四的最後一次支票中，AZN股價下跌0.04％，至76.94美元。
Image by Lydia Ilyakhina via Shutterstock
圖片由 Lydia Ilyakhina 通過 Shutterstock 拍攝
譯文內容由第三人軟體翻譯。